Stelac Advisory Services LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 14,021 shares of the company’s stock, valued at approximately $16,259,000. Eli Lilly and Company comprises about 2.7% of Stelac Advisory Services LLC’s portfolio, making the stock its 10th largest holding.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Integrity Financial Corp WA raised its position in Eli Lilly and Company by 1.3% during the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after purchasing an additional 8 shares in the last quarter. LCM Capital Management Inc lifted its stake in Eli Lilly and Company by 3.3% during the third quarter. LCM Capital Management Inc now owns 253 shares of the company’s stock worth $293,000 after purchasing an additional 8 shares during the last quarter. Smith Shellnut Wilson LLC ADV boosted its holdings in shares of Eli Lilly and Company by 4.1% in the 3rd quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company’s stock worth $235,000 after purchasing an additional 8 shares in the last quarter. Financial Network Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 5.6% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company’s stock worth $175,000 after purchasing an additional 8 shares in the last quarter. Finally, Eads & Heald Wealth Management increased its position in shares of Eli Lilly and Company by 0.5% during the 3rd quarter. Eads & Heald Wealth Management now owns 1,469 shares of the company’s stock valued at $1,700,000 after purchasing an additional 8 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on LLY. Bank of America reissued a “buy” rating and set a $1,497.00 price objective on shares of Eli Lilly and Company in a report on Friday, October 30th. HSBC upped their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. UBS Group increased their price target on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a research report on Friday, October 30th. The Goldman Sachs Group reissued a “buy” rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Finally, Scotiabank boosted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,422.00.
Check Out Our Latest Analysis on Eli Lilly and Company
Top Eli Lilly and Company Stories
Here are a few of the latest stories about LLY:
- Positive Sentiment: New ObesityWeek 2026 results for Lilly’s obesity and cardiometabolic portfolio—including retatrutide, EloraTZP and Foundayo—showed benefits across weight loss and related conditions such as blood-sugar control, sleep apnea and knee osteoarthritis. The breadth of findings supports Lilly’s effort to build a broader cardiometabolic franchise. Article: Positive Trial Results Could Be A Big Moment For Eli Lilly Stock
- Positive Sentiment: Royal Bank of Canada reaffirmed its “outperform” rating and $1,600 price target, implying analyst confidence in further upside. Royal Bank of Canada recommendations
- Neutral Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to add experimental treatments for rare blood cancers. The acquisition broadens its oncology pipeline, but clinical and regulatory milestones will determine the ultimate value and cost. Article: Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Portfolio
Eli Lilly and Company Price Performance
Shares of Eli Lilly and Company stock opened at $1,412.63 on Wednesday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The business’s 50 day simple moving average is $1,253.71 and its two-hundred day simple moving average is $1,114.28. The stock has a market capitalization of $1.33 trillion, a P/E ratio of 45.85, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,475.25.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $7.02 earnings per share. Analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
